Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - levocetirizine dihydrochloride - oral tablet - 5mg

Bandaríkin - enska - NLM (National Library of Medicine)

bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth

Bandaríkin - enska - NLM (National Library of Medicine)

bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the oral r

Bandaríkin - enska - NLM (National Library of Medicine)

physicians total care, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - enter section text here levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 2 to 5 years) with seasonal allergic rhinitis is approved for ucb inc.'s levocetirizine dihydrochloride drug product. however, due to ucb inc.'s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 6 months to 5 years) with perennial allergic rhinitis is approved for ucb inc.'s levocetirizine dihydrochloride drug product. however, due to ucb inc.'s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. levocetirizine dihydrochlorid

Bandaríkin - enska - NLM (National Library of Medicine)

lannett company, inc. - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - cetirizine hydrochloride 5 mg in 5 ml - perennial allergic rhinitis: cetirizine hydrochloride oral solution is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. chronic urticaria: cetirizine hydrochloride oral solution is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. it significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus. cetirizine hydrochloride is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine. there is no information to indicate that abuse or dependency occurs with cetirizine hydrochloride.

Bandaríkin - enska - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - cetirizine hydrochloride 1 mg in 1 ml - perennial allergic rhinitis: cetirizine hydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. chronic urticaria: cetirizine hydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. it significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus. cetirizine hydrochloride is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine. there is no information to indicate that abuse or dependency occurs with cetirizine hydrochloride.

Bandaríkin - enska - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - cetirizine hydrochloride 1 mg in 1 ml - perennial allergic rhinitis : cetirizine hydrochloride oral solution, usp is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. chronic urticaria: cetirizine hydrochloride oral solution, usp is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. it significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus. cetirizine hydrochloride oral solution, usp is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine. there is no information to indicate that abuse or dependency occurs with cetirizine hydrochloride.

Bandaríkin - enska - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cetirizine hydrochloride (unii: 64o047ktoa) (cetirizine - unii:yo7261me24) - cetirizine hydrochloride 1 mg in 1 ml - perennial allergic rhinitis : cetirizine hydrochloride oral solution, usp is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. chronic urticaria: cetirizine hydrochloride oral solution, usp is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. it significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus. cetirizine hydrochloride oral solution, usp is contraindicated in those patients with a known hypersensitivity to it or any of its ingredients or hydroxyzine. there is no information to indicate that abuse or dependency occurs with cetirizine hydrochloride.

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

chanelle medical - cetirizine (cetirizine dihydrochloride) - tablets film-coated - 10mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - levocetirizine dihydrochloride - oral tablet - 5mg